Free lookups: 1/3 Unlock Pro
Clinical reference Find a medicine
Ctrl K
1 of 3 free lookups remaining Upgrade
New search Medicine profile Sennosides

Clinical medicine profile

Sennosides

Therapeutic agent (verify pharmacological class)

POM
Evidence state General guidance Reviewed 14 Aug 2026
Route
See product SmPC
Schedule
POM
ATC
Not assigned
PPB status
registered
Patient advice Check interactions
Verification required

This profile needs source confirmation

Some sections contain general class guidance rather than medicine-specific evidence. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.

01 Risk first

Safety essentials

The information most likely to change a prescribing or dispensing decision.

Contraindications

  • Hypersensitivity to the active substance or excipients.
  • Additional absolute contraindications are indication- and product-specific — consult SmPC.

Precautions

  • Do not use laxative products for longer than 1 week unless directed by a doctor.
  • Ask a doctor or pharmacis before use if you have stomach pain, nausea or vomiting noticed a change in bowel habits that lasts over two weeks.
  • Stop use and ask a doctor if you have rectal bleeding or failure to have a bowel movement after use of a laxative.
  • These may indicate a serious condition.
02 Point of care

Dosing matrix

Population and organ-function guidance, shown together for faster comparison.

Adult

Shake well before using Do not exceed recommended dose Age Starting Dose Maximum Dose adults and children 12 years and older 2-3 teaspoonfuls once a day preferably at bedtime; increase as needed or as recommended by a doctor 3 teaspoons in the morning and 3 teaspoons at bedtime Under 12 years of age ask a doctor ask a doctor

Paediatric

See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.

Renal

Review renal impairment dosing; many agents need CrCl/eGFR adjustment.

  • CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Hepatic

Review hepatic impairment dosing; monitor LFTs if agent is hepatically cleared or hepatotoxic.

03 Clinical use

Use, effects & interactions

Indications

  • relieves occasional constipation (irregularity) generally causes bowel movement in 6 to 12 hours Clinical selection for Sennosides should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
  • Class context: Therapeutic agent (verify pharmacological class).
  • Confirm site-specific dose, duration and monitoring before prescribing.

Adverse effects

  • Excessive bowel activity that may result in diarrhoea
  • abdominal cramps
  • electrolytic imbalances
  • nausea and vomiting
  • non-functional colon due to loss of muscle tone.
  • These are senna glycosides consisting of a number of anthraquinone deriva-tives.
  • Their onset of action is 8-12 hours.
  • Long term use, regular or over-use of laxatives, includ-ing sennosides, can lead to dependency.
  • Drug interactions: Milk, antacids, tetracycline, lipid soluble vitamins [A, D, E and K].
04 Pharmacology

Mechanism & disposition

Stimulant laxatives increase intestinal motility and often cause abdominal cramp.

Stimulant laxatives increase intestinal mo…Mechanism is agent-specific.At receptor, enzyme, ion channel, transpor…
Read complete mechanism

Stimulant laxatives increase intestinal motility and often cause abdominal cramp. Mechanism is agent-specific. At receptor, enzyme, ion channel, transporter or microbial target level, the drug alters a physiological or pathological pathway to produce its therapeutic effect. Confirm precise molecular mechanism in current SmPC / pharmacology reference for this INN before high-stakes decisions.

Onset

Product-specific

Duration

Product-specific

Route

See product SmPC

Elimination

are product-specific. Consider food effects, protein binding, hepatic CYP/UGT

Half-life

when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC.

05 Special populations

Pregnancy, lactation & diet

Pregnancy

Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.

Lactation

Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data.

06 Kenya market

Brands & loaded prices

FromKES 231
MedianKES 231
Listings1
BrandManufacturerPackObserved price
SENNA TABS 50`s Not recorded KES 231.13Daima Chemist price-list reference ↗ Source date not recorded · verify current price
07 Provenance

Sources & review state

Primary sourceLocal active-ingredient clinical extract; FDA drug label via OpenFDA/DailyMed; RxNorm (NLM RxNav); PubChem
Last reviewed14 Aug 2026
EvidenceGeneral guidance
Open source document ↗

Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.